140 results about "Myelin sheaths" patented technology

The invention discloses a fusion protein, a fusion protein gene, a recombinant cell, a recombinant antigen, a reagent for detecting an anti-myelin sheath related glycoprotein antibody and a preparation method, a detection method and application of the reagent, the fusion protein is MAG, GlcAT-P and HNK-1ST fusion protein, and the MAG, GlcAT-P and HNK-1ST fusion protein is formed by sequentially connecting MAG, a GGGGS sequence, EGFP, P2A, GlcAT-P, T2A and HNK-1ST; the amino acid sequence of the MAG, GlcAT-P and HNK-1ST fusion protein is as shown in SEQ ID NO. 1; the kit can be used for detecting the MAG autoantibody, has excellent detection sensitivity and specificity, and can ensure the detection accuracy especially for the detection in a low titer range.

The invention belongs to the technical field of brain dynamics modeling, particularly relates to a regulation and control scheme auxiliary analysis method based on a disease specificity whole brain dynamics model, and aims to realize accurate screening of nerve regulation and control schemes. Comprising the steps that S1, multi-mode magnetic resonance imaging data are obtained and preprocessed, structural connection, a brain region BOLD time sequence, static function connection and dynamic function connection are obtained, and prior constraint values of myelination and cortical atrophy are obtained through calculation based on the preprocessed data; s2, parameterizing the local return coupling strength of the model based on a prior constraint value, coupling the models of different brain regions through the structural connection obtained in the step S1, and constructing a whole brain dynamic model through parameter optimization; s3, training a variational auto-encoder by using different groups of static function connections and dynamic function connections; and S4, applying different regulation and control schemes on the whole brain dynamic model, obtaining a brain state evolution trajectory induced by regulation and control through the trained variational auto-encoder, and screening an effective regulation and control scheme.

A nutritional composition comprising digestible carbohydrates, protein and lipid, wherein the lipid is in the form of lipid globules which are at least partly coated on the surface with phospholipids, for increasing myelination in the brain of an infant who has delayed brain development or is at risk of having delayed brain development.

The invention discloses a nutritional composition for promoting central nervous system development and application. The invention provides a nutritional composition for promoting the development of a central nervous system. The nutritional composition comprises the following necessary components: a breast milk oligosaccharide component and a casein phosphopeptide component, moreover, in the composition, the mass ratio of the breast milk oligosaccharide component to the casein phosphopeptide component is (1-100): (500-1). According to the invention, the breast milk oligosaccharide component and the casein phosphopeptides are matched to prepare the nutritional composition, and the nutritional composition can significantly promote nerve development such as neuronal maturation, synaptic generation and myelin sheath formation.

The invention belongs to the technical field of biomedical materials, and particularly relates to astragaloside-loaded conductive hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: uniformly mixing a methylacrylic anhydride gelatin aqueous solution with an organic solvent solution of astragaloside, and carrying out ultraviolet light cross-linking curing to form methylacrylic anhydride gelatin / astragaloside hydrogel; soaking the obtained hydrogel in hydrochloric acid containing a free radical initiator; then soaking and polymerizing in an aniline ethanol solution; and soaking and purifying to obtain the methylacrylic anhydride gelatin-polyaniline conductive hydrogel loaded with astragaloside. In-vitro experiments prove that the compound has a certain anti-inflammatory effect, can induce neural stem cells to be directionally differentiated into neurons and oligodendrocytes, and is beneficial to promoting nerve regeneration and myelin sheath formation; finally, in-vivo experiments prove that the composition can improve the athletic ability and tissue function recovery of SCI rats, and has a good application prospect.

The invention provides application of tea catechin in preparation of a medicine for preventing and treating bortezomib-induced peripheral neuropathy. A plurality of in-vitro model results show that tea catechin can be used as a copper death inhibitor, remarkably improves related indexes of bortezomib-induced peripheral neuropathy, improves survival rates of Schwanton cells and SH-SY5Y, improves mitochondrial functions and cell cycle abnormalities of the Schwanton cells, reduces intracellular copper ion, cuprous ion and ATP levels, and can be used for preparing the copper death inhibitor for the peripheral neuropathy of the Bortezomib-induced peripheral neuropathy of the Bortezomib-induced peripheral neuropathy. Meanwhile, the death of Schwann cells and SH-SY5Y induced by the copper death inducer is reduced. In-vivo experiments show that the tea catechin plays a role in protecting functional damage of the bortezomib, and the tea catechin remarkably improves mechanical hyperalgesia, gait abnormality and pathological changes of myelin sheath and axon of mice caused by peripheral neuropathy induced by the bortezomib. The tea catechin can be used as a medicine for peripheral neuropathy induced by bortezomib, and has high clinical application value and development prospect.

The present disclosure provides, in one aspect, compounds, compositions, and methods for reducing and / or inhibiting the activity of p38gamma. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for promoting remyelination. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for treating, preventing, and / or ameliorating one or more diseases or disorders in a subject, including but not limited to multiple sclerosis (MS), inflammatory disease, and cancer.

The invention belongs to the technical field of biological medicine, and particularly relates to a single-domain antibody VHH-L1 targeting LINGO-1 protein, and the amino acid sequence of the single-domain antibody VHH-L1 is shown as SEQ ID NO: 1. The single-domain antibody has nanomole-level high affinity and excellent specificity, can effectively block the interaction between LINGO-1 and ligands thereof, and remarkably promotes differentiation and myelination of oligodendroglia cells. The invention further provides a neural stem cell subjected to genetic engineering modification, and the neural stem cell can stably and continuously secrete the single-domain antibody VHH-L1. In a spinal cord injury animal model, the engineered stem cell shows an excellent treatment effect, can significantly promote motor function recovery, axon regeneration and myelin sheath repair, and effectively inhibits glial scar formation. The double advantages of cell therapy and long-acting protein delivery are fused, and a brand new efficient treatment strategy is provided for demyelination diseases such as multiple sclerosis and spinal cord injury.

The present invention relates to a kit of nutrient blend compositions for young individuals, in particular children aged between 0 and 66 months, each one of the compositions having age-specific ingredients. The kit of nutrient blend compositions is specifically aimed at promoting myelination of targeted brain regions, in particular the social brain, of children at specific ages and stages of brain development.

The invention discloses an application of fenoterol hydrobromide and pharmaceutically acceptable salt thereof in preparation of a medicine for treating diabetic peripheral neuropathy. The fenoterol hydrobromide and the pharmaceutically acceptable salt thereof have obvious effects of promoting growth of peripheral sensory neurite and protecting myelin sheath injury, and can improve symptoms of slow nerve conduction speed and sensory deficiency induced by diabetes mellitus.

The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

A method for determination of an indicator representative of a change in the brain caused by a demyelinating disease, the method including, for each region of interest of the brain, determining a regional coefficient of one of the following diffusion coefficients: the radial diffusion, the axial diffusion, the mean diffusion, the anisotropy fraction, or a combination of several of these coefficients, the regional coefficients being determined from a diffusion MRI image; determining a number of changed regions, for which a condition relating to the value of the regional diffusion coefficient of each region is satisfied; and determining the indicator in accordance with the number of changed regions.

Disclosed herein are methods and compositions for treating a demyelinating disease, such as multiple sclerosis, by administering to a subject suffering from the disease at least one Retinoid X receptor gamma (RXRy) agonist and at least one member selected from a Liver X Receptor (LXR) antagonist, CYP51 inhibitor, TM7SF2 inhibitor, EBP inhibitor, and combinations thereof.

The application belongs to the technical field of medicine, and particularly relates to application of echinacoside in preparation of a medicine for preventing or treating a demyelination disease; the echinacoside can promote differentiation and maturation of OPCs to OLs, promote proliferation of OLs, promote myelin repair, improve pathological changes of myelin ultrastructure, and promote myelin thickness to return to a normal level; the scheme provides a new treatment means for preventing or treating the demyelination disease, and is expected to reverse disability caused by myelin shedding or damage.

The invention discloses a macrophage-platelet targeting delivery system carrying genes and mitochondria as well as a preparation method and application of the macrophage-platelet targeting delivery system. The platelet loaded with the PPAR gamma gene nano-composite is covalently linked to the surface of macrophage through a click chemical reaction, and a novel cell composite carrier is constructed. According to the system, the natural chemotaxis of macrophages to an injured part is fully utilized to realize precise targeting, and PPAR gamma genes and functional mitochondria are synchronously released through platelet activation in an injured microenvironment, so that the energy metabolism and lipid homeostasis of the macrophages are cooperatively regulated and controlled, the cellular burial function of the macrophages is effectively recovered, and tissue repair and regeneration are promoted. Experimental results show that the delivery system is reliable in preparation method and high in targeting efficiency, axon regeneration, myelin sheath repair and motor function recovery can be remarkably promoted in a spinal cord injury model, and a brand-new synergistic treatment strategy is provided for tissue injury repair.

The invention discloses a dietary therapy formula for preventing senile dementia, improving memory, repairing a conducted nervous system and dredging damaged brain nerves, and belongs to the technical field of dietary therapy health care. According to the formula, functional nutritional ingredients, bioactive peptides, medicinal and edible extracts and compound probiotics are taken as cores, and the formula is prepared through scientific proportioning; the health-care food specifically comprises xylitol, isomaltooligosacharide, N-acetylneuraminic acid, phosphatidylserine, bovine brain peptide, walnut peptide, shark peptide, acer truncatum seed oil microcapsule powder, DHA algal oil microcapsule powder, spina date seeds, tea theanine, gamma-aminobutyric acid, Belgian imported inulin, magnesium stearate, and 16 optional specific probiotics and metabiotics. The formula follows a multi-dimensional synergistic principle of nutrition supply-nerve repair-function regulation-absorption synergy, the core component can penetrate through a blood brain barrier, supplement nerve repair raw materials, repair damaged nerve cells and myelin sheaths and regulate neurotransmitter balance, and the probiotics indirectly assist nerve maintenance through intestinal tract-nerve axis, so that the composition has the effects of promoting blood circulation and promoting blood circulation. The synergistic effects of preventing senile dementia, improving memory and repairing and dredging a nervous system are achieved; the raw materials are food-grade safe components, have no side effects, can be prepared into powder, tablet candies and other forms, are convenient to eat and suitable for long-term conditioning, and solve the problems of single component, insufficient repair pertinence and low absorption efficiency of existing nerve care products.

The subject matter described herein relates to compounds of Formula A and pharmaceutically acceptable salts thereof that promote myelination, methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds to treat conditions, such as myelination-related conditions.

The present application relates to a kind of myelin repair auxiliary method based on neural signal modeling.The method obtains the multi-modal neural signal data such as electroencephalogram signal of individual to be rehabilitated and is preprocessed, forms preprocessed data set;Subsequently, individualized time series modeling process is executed, and the time series characteristic representation including nerve conduction velocity recovery rate, phase consistency and neural pathway integrity is generated, and individualized calibration is carried out by dynamic baseline updating mechanism.The calibrated feature representation is input to the pre-trained deep learning inference engine.The inference engine outputs myelin repair index and imbalance risk score, which is used to represent the degree of repair and predict future abnormal risk.Based on the above index, a set of intervention parameters is generated, including electrical stimulation intervention parameters, virtual rehabilitation training task difficulty and rehabilitation training rhythm, and further forming control instructions to configure virtual rehabilitation training environment and electrical stimulation execution interface, so as to realize the individualized assistance and dynamic optimization of myelin regeneration repair.

The invention discloses a method for constructing a neurodevelopmental disorder animal model based on central nervous system myelin sheath function change and application, and belongs to the technical field of biological engineering. An Msl2 gene conditional knockout mouse model is constructed by adopting a gene engineering technology, the space-time specific knockout of a second exon of the Msl2 gene in a specific cell type is realized through a Cre-LoxP recombinase system, and the exon encodes a key enzyme activity region for catalyzing ubiquitination. Model construction is based on central nervous system oligodendrocyte / myelin sheath dysfunction, the behavior phenotype of the model is similar to the behavior of a typical neurodevelopment disorder animal, a brand new perspective is provided for exploring an etiology mechanism, model mice can be prepared on a large scale by performing directional mating on the gene modified mice, and the development of the model is promoted. And consistency of different experiment batches and reliable reproduction of experiment data are ensured.

The invention relates to the technical field of new application of medicines, in particular to application of G15 to treatment of white matter injury based on promotion of cerebrovascular generation, and finds that the G15 has the effect of promoting cerebrovascular generation, can promote myelination insufficiency caused by hypoxia in the early development stage and can improve neurological dysfunction caused by hypoxia, and the G15 has the effect of promoting cerebrovascular generation. Moreover, myelin sheath regeneration of a local demyelination area after the adult can be promoted, so that the effect of directly treating the white matter injury from the pathological aspect is achieved. The invention provides a new application of G15 in treating white matter injury and long-term neurological dysfunction by promoting cerebrovascular generation.

A novel method of treatment for treating a neurological disease or condition. It involves a compound of Formula (I) or a pharmaceutically or veterinarily acceptable salt thereof, or any stereoisomer or mixture of stereoisomers of a compound of Formula (I) or any pharmaceutically or veterinarily acceptable salt thereof, for use in the treatment or prevention of a neurological disease or condition that results in the destruction or degeneration of neurons, axons, or myelin, wherein R1, R2, and R3 are as defined herein, wherein the treatment comprises: a) a first period of 1 to 7 days, wherein the compound is administered one or more times to a subject in need thereof, and b) a second period of equal to or longer than 13 days, wherein the compound is not administered, wherein the second period occurs after the first period and before the next administration of the compound.

The present disclosure provides the use of ATDR and ATDRA in the treatment of white matter diseases, and in particular provides all trans-13, 14-dihydroretinol (ATDR) and / or all trans-13, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt comprising all trans-13, 14-dihydroretinol (ATDR) and / or all trans-13, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt comprising all trans-13, 14-dihydroretinoic acid (ATDRA) and / or all trans-13, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof. The present invention relates to a composition comprising 1, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, retinol saturase (Retsat) or a variant thereof, a nucleic acid encoding Retsat or a variant thereof, an expression cassette comprising a nucleic acid encoding Retsat or a variant thereof, a vector comprising a nucleic acid encoding Retsat or a variant thereof, and a method for preparing the same. Use of a cell expressing Retsat or a variant thereof for the preparation of a medicament for the prevention and / or treatment of leukoencephalopathy in a subject in need thereof, which promotes oligodendrocyte differentiation and myelination to thereby treat leukoencephalopathy.

Provided herein are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of TUBB4A RNA and, in some cases, the amount of TUBB4A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful for ameliorating at least one symptom of a disease or condition associated with TUBB4A. Such symptoms and markers include hypomyelination, demyelination, dysphonia, myodynia, ataxia, spasm, cerebellar and / or basilar joint atrophy, hypopsia, stiffness, microcephalic deformity, focal cortical dysplasia, seizures, and kindergarten death.

The present application relates to the use of clemastine in the manufacture of a medicament for the treatment of depression. The present application first discovered that clemastine has the efficacy of treating depression, and clemastine can effectively alleviate the depression-like phenotype of mice induced by chronic unpredictable mild stimulation or lipopolysaccharide by promoting oligodendrocyte myelination.

The application belongs to the technical field of spinal cord injury repair, and particularly relates to a biologically active titanium carbide-metal ion conductive hydrogel as well as a preparation method and application thereof. The biologically active titanium carbide-metal ion conductive hydrogel is formed by dynamic covalent bond crosslinking of two-dimensional titanium carbide-metal ion composite nanosheets, aldehyde-based hyaluronic acid and amino-based gelatin. The conductive hydrogel prepared by the application can effectively remove excess ROS at an injury site, reduce neuron oxidative stress, effectively promote axon regeneration, myelin sheath formation and neural network reconstruction, and thus accelerate recovery of motor function.

This invention relates to the field of biomedical technology, and provides the application of compound LY2940094 in the preparation of drugs for treating demyelinating diseases of the central nervous system. This invention verifies through modern biological techniques that compound LY2940094 can promote the differentiation of oligodendrocyte precursor cells (OPCs) into mature oligodendrocytes (OLs), thereby promoting the regeneration of myelin in the central nervous system and thus treating demyelinating diseases of the central nervous system.

The present application provides O-GlcNAc glycosidase (O-GlcNAcase, OGA) inhibitors and their applications for promoting remyelination. Specifically, by comparing the promoting effects of different types of OGA inhibitors on OPC differentiation and remyelination in the models of OPC differentiation and remyelination, the OGA inhibitors with drugability of the present application are obtained. The OGA inhibitors of the present application have wide application value in preventing and / or treating demyelination and its related diseases.

The invention provides a gene mutant and application thereof, and belongs to the technical field of gene detection. Specifically, compared with a wild ATRN gene, the nucleotide sequence of the gene mutant provided by the invention has the following mutations: c.1504Ggt; t; wherein the nucleic acid is DNA (Deoxyribose Nucleic Acid). According to the application, the pathogenic gene ATRN having a causal relationship with schizophrenia is confirmed, and mutation influencing the gene function may cause myelin sheath injury so as to cause schizophrenia.

Compositions and methods for treating, preventing, or reversing neuroinflammation-related disorders or autoimmune neurological disorders in a subject in need thereof are disclosed. The methods comprise administering a therapeutically effective amount of a composition comprising a myelin basic protein (MBP) peptide.